BioMarin Pharmaceuticals BMRN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's cash & equivalents?
- BioMarin Pharmaceuticals (BMRN) reported cash & equivalents of $3.07B in Q1 2026.
- How has BioMarin Pharmaceuticals's cash & equivalents changed year-over-year?
- BioMarin Pharmaceuticals's cash & equivalents increased by 192.9% year-over-year, from $1.05B to $3.07B.
- What is the long-term trend for BioMarin Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's cash & equivalents has grown at a 15.1% compound annual growth rate (CAGR), from $649.16M to $1.31B.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and financial flexibility, while a decrease may indicate heavy cash burn or significant capital deployment.
- How does cash & equivalents compare across companies?
- Biotech firms typically maintain higher cash balances than mature industries to fund long-term clinical trials and commercial launches.